Omron Healthcare and physIQ Partner to Transform Cardiovascular Patient Care
- Omron HeartGuide™, the first wearable blood pressure device, will integrate with physIQ’s pinpointIQ® analytics platform to indicate a potential health risk
- This combined solution is being deployed to help manage recently-discharged, at-risk patients
- The goal is to provide clinicians with physiological insight to proactively address potential clinical deterioration
The Omron HeartGuide, which recently announced its retail availability at the 2019 Consumer Electronics Show (CES) and awarded the Engadget “Best of CES” award for best wearable, is a first-of-its kind wearable blood pressure monitor made in the convenient form of a wristwatch. It uses oscillometric technology to measure medically-accurate blood pressure readings and monitors activity and sleep. PhysIQ’s pinpointIQsolution is an enterprise-ready, device-agnostic platform designed to capture continuous multivariate physiological data from wearable sensors, apply FDA-cleared Artificial Intelligence-based analytics, and provide actionable clinical information to a patient’s care team. Collectively, the combined solution represents an opportunity to enable a proactive care delivery model to better support at-risk patients at home.
“At Omron, our mission is Going for Zero, the elimination of heart attack and stroke,” said Ranndy Kellogg, president and CEO of Omron Healthcare, Inc. “HeartGuide is a significant step forward in Going for Zero and the addition of advanced analytics builds on that advancement to give even higher risk patients greater power in managing their condition and reducing their risk of an event. We are committed to working with physIQ to leverage their industry-leading platform and human physiology analytics to provide better care for patients.”
The initial implementation of the combined solution will be with a major Chicago-area integrated health system and focus on supporting post-discharge patients who have been hospitalized for either heart failure or heart attack. Patients will wear HeartGuide, which will transmit data through the physIQ mobile app to the pinpointIQcloud-based platform. Clinicians will access patient data and analytics through the pinpointIQ user interface such that they can proactively manage their at-risk patients.
“We have long believed that high-frequency ‘real world’ blood pressure was a parameter that could unlock unprecedented visibility into patient physiology,” shared Gary Conkright, CEO of physIQ. “By integrating HeartGuide into our pinpointIQ platform, we are confident that we have an end-to-end solution that will address a massive unmet need in the market and bring enormous value to patients and their clinicians. This is the beginning of a relationship that we believe will truly transform how patients are cared for at home.”
Cardiovascular disease is the leading cause of death in the U.S. with Americans suffering 760,000 heart attacks each year. In addition, 5.7 million adults live with heart failure, resulting in more than 1 million hospitalizations annually. By virtue of continuously capturing clinical grade data and leveraging machine learning-based analytics, Omron and physIQ share the goal to reduce complications post-discharge and more effectively manage these patients as they navigate life after hospitalization.
About Omron Healthcare, Inc.
Omron Healthcare, Inc.is the world’s leading manufacturer and distributor of personal heart health and wellness products. Its market-leading products include home blood pressure monitors and electrotherapy devices. Since Omron invented its first blood pressure monitors more than 40 years ago, the company has been passionate about empowering people to take charge of their health at home through precise technology. Omron is the number one doctor and pharmacist recommended brand of blood pressure monitors for home use. The company’s mission is Going for Zero, the elimination of heart attacks and strokes. For more information, visit OmronHealthcare.com.
PhysIQ is a company dedicated to enabling proactive care delivery models through pinpointIQ® , our highly scalable cloud-based platform for personalized physiology analytics. Our FDA 510k-cleared data analytics platform is designed to process multiple vital signs from wearable sensors to create a personalized dynamic baseline for each individual. By mapping vital sign relationships this way, physIQ’s analytics detect subtle deviations that may be a precursor to disease exacerbation or change in health. With applications in both healthcare and clinical trial support, physIQ is transforming continuous physiological data into insight for providers, health systems, payers, and pharmaceutical and medical device companies. For more information, please visit www.physiq.com. Follow us on Twitter and LinkedIn.